Pharmaceutical News Pharmaceutical News Rss feed

  • Aspen seeks to acquire GSK thrombosis drug and plant Aspen seeks to acquire GSK thrombosis drug and plant

    DURBAN / LONDON - South Africa's biggest generic drug maker Aspen Pharmacare and its subsidiary Aspen Global Incorporated have made an offer to acquire thrombosis drugs and their associated manufacturing site at Notre Dame de Bondeville, France, from GlaxoSmithKline (GSK). "AGI will acquire from GSK the Arixtra and Fraxiparine/Fraxodi brands and business worldwide, except in China, Pakistan ...

  • How Much Teva Agrees To Disclose Executive Pay

    In a few months, we will know exactly how much Teva Pharmaceutical compensates ceo Jeremy Levin. The drugmaker has agreed to settle a ...

  • Mapi Pharma obtains US patent for Tapentadol analgesic

    Mapi Pharma has obtained US patent protecting process and preparation of Tapentadol, indicated for the oral treatment of moderate to severe-acute pain in the US and Europe. The US patent is titled 'Intermediate Compounds and Processes for the Preparation of Tapentadol and Related Compounds'. Using easily available reagents, the patented and cost effective process fitting scalable ...

  • Daiichi Sankyo seeks approval for oral antiplatelet agent in Japan

    Daiichi Sankyo Company is seeking approval for an oral antiplatelet agent prasugrel hydrochloride to treat ischemic heart diseased patients undergoing percutaneous coronary intervention (PCI) in Japan. The company has submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for prasugrel. Data from phase 3 trial carried out in Japanese patients with acute coronary ...

  • T3D Therapeutics wins exclusive global rights to DB959 from DARA BioSciences

    T3D Therapeutics has obtained exclusive global rights to develop and commercialize oral, highly selective, dual nuclear receptor agonist DB959 from DARA BioSciences. Targeting peroxisome proliferator activated receptor delta (PPARd), DB959 was developed by DARA through Phase 1 trials for the treatment of diabetes and dyslipidemia. As per the company's strategic plan to focus on the ...


clear
Toronto Weather
16°C Clear
Winds: From the ENE at 8 MPH
Thu
clear
21° 11°
Fri
partlycloudy
23° 14°
Sat
partlycloudy
24° 15°
Last Updated on June 19, 9:00 AM EDT
Weather sourced from Weather Underground

Movie Review

Oleanna

David Mamet's play-turned-film, "Oleanna," is about a number of things -- sexual harassment, higher education, the battle of the sexes, the role of the middle class -- but more than anything, it is about power. The film takes two characters, a pedantic liberal arts professor named John (William H. Macy) and a confused, female student named Carol (Debra Eisenstadt), and depicts their desire for pow ... ...

On Facebook

  • Eli Lilly exercises rights to type 2 diabetes drug under deal with Transition Therapeutics

    Eli Lilly and Company has opted to presume all development and commercialization rights to type 2 diabetes drug candidate, TT-401, under the deal with Transition Therapeutics. The assumption of rights to TT-401, a dual agonist of the Glucagon-Like Peptide-1 and glucagon receptors, by Eli Lilly triggers a $7m milestone payment to Transition. As per the amended agreement between the companies, ...

  • Civitas wins second MJFF grant to advance CVT-301 research

    The Michael J. Fox Foundation for Parkinson's Research (MJFF) has announced a second grant to Civitas Therapeutics to advance the research of its lead product CVT-301. The $1m funding will support later stage clinical trial of inhaled formulation of levodopa that is developed as an adjunct PRN therapy offering relief from intermittent debilitating motor fluctuations (OFF) impacting a ...

  • NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

    The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, ...

  • 3 New Fat-Busting Supplements For Speedy Weight Loss

    Resveratrol, derived from grapes and red wine, may or may not turn back the clock, but it appears to peel off pounds (Photo: Photobucket public domain) How much more news about weight loss supplements can there be to share? More every year, it turns out, as researchers synthesize new plant-derived compounds and test methods to optimize them for effectiveness. Based on studies released in the ...

  • Almunia fines Lundbeck and rivals for fudging competition on medicines

    European Commission Vice-President Joaqun Almunia announced on Wednesday (June 19) fines totalling nearly €150 million on pharmaceutical companies that the Commission judges guilty of illicit agreements to blunt competition in the market for anti-depressant medicines. Lundbeck, a Danish company, is fined €93.8 million, and a handful of generic companies are fined a total of € 52.2 ...

More Pharmaceutical News